HomeComparePAIOF vs PLD

PAIOF vs PLD: Dividend Comparison 2026

PAIOF yields 20000.00% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PAIOF wins by $52481917574412746752.00M in total portfolio value
10 years
PAIOF
PAIOF
● Live price
20000.00%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$52481917574412746752.00M
Annual income
$51,970,745,957,167,775,000,000,000.00
Full PAIOF calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — PAIOF vs PLD

📍 PAIOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPAIOFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PAIOF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PAIOF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PAIOF
Annual income on $10K today (after 15% tax)
$1,700,000.00/yr
After 10yr DRIP, annual income (after tax)
$44,175,134,063,592,610,000,000,000.00/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, PAIOF beats the other by $44,175,134,063,592,610,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PAIOF + PLD for your $10,000?

PAIOF: 50%PLD: 50%
100% PLD50/50100% PAIOF
Portfolio after 10yr
$26240958787206373376.00M
Annual income
$25,985,372,978,583,888,000,000,000.00/yr
Blended yield
99.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

PAIOF
No analyst data
Altman Z
-10.7
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PAIOF buys
0
PLD buys
0
No recent congressional trades found for PAIOF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPAIOFPLD
Forward yield20000.00%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$52481917574412746752.00M$6.50M
Annual income after 10y$51,970,745,957,167,775,000,000,000.00$5,256,436.18
Total dividends collected$52448189483771600896.00M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: PAIOF vs PLD ($10,000, DRIP)

YearPAIOF PortfolioPAIOF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$2,010,700$2,000,000.00$11,255$555.24+$2.00MPAIOF
2$377,983,225$375,831,775.70$13,062$1,018.59+$377.97MPAIOF
3$66,433,479,469$66,029,037,418.28$15,903$1,926.67+$66433.46MPAIOF
4$10,916,985,471,987$10,845,901,648,955.73$20,839$3,823.32+$10916985.45MPAIOF
5$1,677,384,363,769,318$1,665,703,189,314,291.80$30,464$8,166.08+$1677384363.74MPAIOF
6$240,985,175,079,139,100$239,190,373,809,905,920.00$52,054$19,457.30+$240985175079.09MPAIOF
7$32,373,573,631,143,694,000$32,115,719,493,809,017,000.00$109,886$54,188.93+$32373573631143.58MPAIOF
8$4,066,766,648,320,630,000,000$4,032,126,924,535,306,000,000.00$304,030$186,451.18+$4066766648320629.50MPAIOF
9$477,730,483,406,513,300,000,000$473,379,043,092,810,300,000,000.00$1,166,125$840,813.32+$477730483406513344.00MPAIOF
10$52,481,917,574,412,750,000,000,000$51,970,745,957,167,775,000,000,000.00$6,504,190$5,256,436.18+$52481917574412746752.00MPAIOF

PAIOF vs PLD: Complete Analysis 2026

PAIOFStock

Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.

Full PAIOF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this PAIOF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PAIOF vs SCHDPAIOF vs JEPIPAIOF vs OPAIOF vs KOPAIOF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.